May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Chronic N–4–Hydroxyphenyl Retinamide Treatment Augments Laser Induced Choroidal Neovascularization in Mice
Author Affiliations & Notes
  • J. Zhou
    Ophthalmology, Arnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, Keck School of Medicine at the University of Southern California, Los Angeles, CA
  • J. Sohn
    Ophthalmology, Arnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, Keck School of Medicine at the University of Southern California, Los Angeles, CA
  • C. Spee
    Ophthalmology, Arnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, Keck School of Medicine at the University of Southern California, Los Angeles, CA
  • S.J. Ryan
    Ophthalmology, Arnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, Keck School of Medicine at the University of Southern California, Los Angeles, CA
  • B. Maurer
    Childrens Hospital, Los Angeles, CA
  • R. Kannan
    Ophthalmology, Arnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, Keck School of Medicine at the University of Southern California, Los Angeles, CA
  • D.R. Hinton
    Ophthalmology, Arnold and Mabel Beckman Macular Research Center, Doheny Eye Institute, Keck School of Medicine at the University of Southern California, Los Angeles, CA
    Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA
  • Footnotes
    Commercial Relationships  J. Zhou, None; J. Sohn, None; C. Spee, None; S.J. Ryan, None; B. Maurer, None; R. Kannan, None; D.R. Hinton, None.
  • Footnotes
    Support  NIH grants EY01545 and EY03040, The Arnold and Mabel Beckman Foundation, RPB
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 1417. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Zhou, J. Sohn, C. Spee, S.J. Ryan, B. Maurer, R. Kannan, D.R. Hinton; Chronic N–4–Hydroxyphenyl Retinamide Treatment Augments Laser Induced Choroidal Neovascularization in Mice . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1417.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : N–4–hydroxyphenyl retinamide (4–HPR; fenretinide) is a retinoic acid derivative and a stimulator of endogenous ceramide biosynthesis that has been shown to be cytotoxic to tumor cells. Generation of reactive oxygen species is one mechanism by which 4–HPR causes cytotoxicity. The purpose of the study was to assess the effect of chronic administration of 4–HPR on laser induced choroidal neovascularization (CNV) in mice.

Methods: : Focal laser photocoagulation (Diode green laser, 75–µm spot size, 0.1–second duration, 140 mW) was applied to eyes of adult, male C57BL/6 mice. Three laser photocoagulation burns were delivered to the retina, lateral to the optic disc through a slit lamp using a coverglass as a contact lens. 4–HPR (1mg, 0.4ml) or vehicle was injected intraperitoneally 2x daily for 14 days after laser photocoagulation. Fluorescein angiograms (FA) and histological examinations were performed at day 7 and day 14 after laser surgery.

Results: : Administration of 4–HPR resulted in increased levels of vascular leakage shown by FA. Histological studies revealed increased CNV lesion size in mice treated with 4–HPR compared to controls. In addition, there were fewer retinal pigmented epithelial cells in the CNV lesions of mice treated with 4–HPR compared to controls.

Conclusions: : 4–HPR treatment resulted in increased CNV as compared to controls, possibly due to increased oxidative stress. The exact mechanism of action of 4–HPR remains to be elucidated.

Keywords: choroid: neovascularization • oxidation/oxidative or free radical damage • age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×